; and (B) publish on the Internet website of the Food and Drug Administration such information under subparagraph (A) with respect to drugs for which there are three or fewer application holders; and (C) update the information published pursuant to subparagraph (B) every 180 days. (2) Contents The public information maintained and published under paragraph (1)(B) shall include— (A) the name of the drug, name of the holder of the approved application, and the marketing status for each drug; and (B) an indication of whether the Secretary considers the drug to be for the treatment or prevention of a serious disease or medical condition, for which there is no alternative drug that is judged by medical professionals to be an adequate substitute available in adequate supply. (c) Public health exception The Secretary may choose not to make information collected under this section publicly available if the Secretary determines that disclosure of such information would adversely affect the public health. (d) Notification When the Secretary first publishes the information under subsection (b), the Secretary shall notify relevant Federal agencies, including the Centers for Medicare & Medicaid Services and the Federal Trade Commission, that the information has been published and will be updated regularly. . 203. Suitability petitions (a) In general It is the sense of the Senate that the Food and Drug Administration shall meet the requirement under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(C) ) and section 314.93(e) of title 21, Code of Federal Regulations, of responding to suitability petitions within 90 days of submission. (b) Report The Secretary of Health and Human Services shall include in the annual reports under section 102(b)— (1) the number of pending petitions under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(C) )